Why did the Race Oncology (ASX:RAC) share price drop 10% today?

What happened with Race shares today?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Race Oncology share price slipped almost 10% today
  • It hit a new 12 month low during intraday trading 
  • Today's fall has dragged Race shares more than 36% lower in 2022 so far

Today wasn't a great day for most ASX shares. The All Ordinaries Index (ASX: XAO) ended up losing 0.93% over this Tuesday's trading session. But that loss was eclipsed by the Race Oncology Ltd (ASX: RAC) share price.

Race shares ended up finishing at $2.30 a share, down a nasty 9.8% for the day. What's worse, the company hit $2.27 during intra-day trading a new 52-week low for Race Oncology. That puts the company's losses over 2022 so far at 36%, including 17.3% over the past 5 trading days. Its 12-month loss now stands at 38%.

So why did this company have such a lousy day of trading today?

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.

Image source: Getty Images

Race to the bottom for Race Oncology share price

Well, unfortunately, it's not entirely clear. There were no announcements or news out of the company to speak of. Nor have there been since a major update in January, which was an activities update for the December quarter. Back then, the company announced that its capital raising had been successful and oversubscribed at $3 a share. Race also reported a healthy cash position as well as a "preclinical discovery into heart protection during cancer treatment".

That caused the Race share price to rise at the time. But investors appear to have forgotten all about those developments today.

So while it's unclear exactly what spooked investors today, it could just be the nature of the company itself. As a small-cap ASX share with a market capitalisation of just over $400 million, Race is a company that could have been treated as a more speculative investment by some of its shareholders. As such, on a day like today when investors didn't seem in the mood to take risks, Race shares might have just been the victim of some fear-provoked selling pressure.

Whatever the reasons for today's sell off, Race shareholders will undoubtedly be hoping for better fortunes over the rest of the week.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this ASX healthcare stock is a top rebound candidate with big upside 

This could be a perfect buy-low candidate.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

2 ASX healthcare stocks tipped to return 34% to 63%

These companies could be poised for much bigger things.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
ASX Share Market News

Are Pro Medicus shares now too cheap to ignore?

The discount looks tempting, but slowing growth could expose valuation risks.

Read more »

Two ASX share investors sharing a secret.
Healthcare Shares

Cochlear shares are quietly rebounding: Is a bigger rally coming?

After a 58% plunge, Cochlear doesn’t need perfection to surprise investors.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech is tipped to more than double in value

Encouraging trial results have the analysts excited.

Read more »

person climbing mountain
Healthcare Shares

CSL share price forecast: How high could it climb in the next year?

CSL shares could roar back, but investors need more than hope.

Read more »

Two CEOs shaking hands on a deal.
Healthcare Shares

Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

Read more »

Woman looking at stock market numbers.
Healthcare Shares

CSL shares are rising: 3 things investors need to watch

CSL’s FY26 result could reveal whether the turnaround has finally begun.

Read more »